• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Document Reviewers: Luis Alcocer (Mexico), Christina Antza (Greece), Mustafa Arici
(Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luıs Bronze (Portugal), John …

Background Alteplase is the standard agent used in early reperfusion therapy, but
alternative thrombolytic agents are needed. The efficacy and safety of reteplase as …

These guidelines will be updated every four years. Vascular centres are encouraged to audit
implementations made as a result of the guidelines. Audit cycles should be repeated and …

Background There is increasing interest in replacing alteplase with tenecteplase as the
preferred thrombolytic treatment for patients with acute ischaemic stroke. We aimed to …

Background Whether thrombectomy alone is equally as effective as intravenous alteplase
plus thrombectomy remains controversial. We aimed to determine whether thrombectomy …

Background Tenecteplase is a modified tissue plasminogen activator with pharmacological
and practical advantages over alteplase—which is currently the only approved thrombolytic …

Background Intravenous thrombolysis with alteplase bolus followed by infusion is a global
standard of care for patients with acute ischaemic stroke. We aimed to determine whether …

Alteplase is currently the only approved thrombolytic agent for treatment of acute ischaemic
stroke, but interest is burgeoning in the development of new thrombolytic agents for systemic …